lifestyle.longislandreport.org

Author: Dynavax Technologies

Sanofi to Acquire Dynavax, Adding a Marketed Adult Hepatitis B Vaccine and Phase 1/2 Shingles Candidate to the Pipeline

January 6, 2026
Sanofi to Acquire Dynavax, Adding a Marketed Adult Hepatitis B Vaccine and Phase 1/2 Shingles Candidate to the Pipeline

January 6, 2026
Dynavax to Participate at the 8th Annual Evercore Healthcare Conference

November 22, 2025
Dynavax Enters Exclusive License Agreement for Vaxart’s Novel Oral COVID-19 Vaccine Program

November 8, 2025
Dynavax to Report Third Quarter 2025 Financial Results and Host Conference Call on November 5, 2025

October 23, 2025
Dynavax Presents Positive Topline Data from Part 1 of Phase 1/2 Trial for Shingles Vaccine Candidate at IDWeek 2025 and Announces Initiation of Part 2 of Trial

October 22, 2025